论文部分内容阅读
目的研究分析恩替卡韦联合虎驹乙肝胶囊治疗乙型肝炎e抗原(HBeAg)阳性慢性乙型肝炎的效果。方法 100例HBeAg阳性慢性乙型肝炎患者为本次研究对象,按照随机数字表法分成对照组及治疗组,每组50例。对照组患者采用恩替卡韦治疗,治疗组患者采用恩替卡韦联合虎驹乙肝胶囊治疗。比较两组患者治疗12、24、48周时乙肝病毒脱氧核糖核酸(HBV-DNA)、HBeAg阴转率,随访1年比较两组患者不良反应发生情况。结果治疗12、48周时,两组患者的HBV-DNA转阴率比较,差异均无统计学意义(P>0.05);治疗24周时,治疗组患者的HBV-DNA转阴率为76%,高于对照组的56%,差异具有统计学意义(P<0.05)。两组患者治疗12、24、48周时的HBeAg阴转率比较,差异均无统计学意义(P>0.05)。治疗组患者的不良反应发生率为8%,与对照组的10%比较,差异无统计学意义(P>0.05)。结论恩替卡韦联合虎驹乙肝胶囊治疗HBeAg阳性慢性乙型肝炎起效快,治疗效果肯定,不良反应少,值得临床推广。
Objective To study the effect of entecavir combined with Huju Hegan capsule in the treatment of hepatitis B e antigen (HBeAg) -positive chronic hepatitis B. Methods 100 cases of HBeAg-positive chronic hepatitis B patients were divided into control group and treatment group according to random number table method, with 50 cases in each group. Patients in the control group were treated with entecavir, and patients in the treatment group were treated with entecavir in combination with Tiger foal hepatitis B capsule. The incidence of HBV-DNA and HBeAg negative conversion in the two groups were compared between the two groups at 12, 24 and 48 weeks of follow-up. The incidence of adverse reactions was compared between the two groups after one year of follow-up. Results At 12 and 48 weeks of treatment, the HBV-DNA negative rates in the two groups were not significantly different (P> 0.05). At 24 weeks, the HBV-DNA negative rates in the treatment group were 76% , Higher than 56% of the control group, the difference was statistically significant (P <0.05). There was no significant difference in HBeAg negative conversion rate between the two groups at 12, 24 and 48 weeks (P> 0.05). The incidence of adverse reactions in the treatment group was 8%, which was not significantly different from that in the control group (P> 0.05). Conclusion Entecavir combined with Huju hepatitis B capsule in the treatment of HBeAg-positive chronic hepatitis B has rapid onset, definite treatment effect and few adverse reactions, which is worthy of clinical promotion.